Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Laura M. Luh, U. Scheib, Katrin Juenemann, et al.
Angewandte Chemie International Edition (2020) Vol. 59, Iss. 36, pp. 15448-15466
Open Access | Times Cited: 149

Showing 1-25 of 149 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1824
Targeted protein degradation: mechanisms, strategies and application
Lin Zhao, Jia Zhao, Kunhong Zhong, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 405
Put a ring on it: application of small aliphatic rings in medicinal chemistry
Matthias R. Bauer, Paolo Di Fruscia, Simon C. C. Lucas, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 4, pp. 448-471
Open Access | Times Cited: 294
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Dean G. Brown, Heike J. Wobst
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2312-2338
Closed Access | Times Cited: 216
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
Michael J. Bond, Craig M. Crews
RSC Chemical Biology (2021) Vol. 2, Iss. 3, pp. 725-742
Open Access | Times Cited: 161
Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes
Yanyan Miao, Qianqian Gao, Menghan Mao, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 20, pp. 11267-11271
Closed Access | Times Cited: 128
Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic
Janet M. Sasso, Rumiana Tenchov, Dasheng Wang, et al.
Biochemistry (2022) Vol. 62, Iss. 3, pp. 601-623
Open Access | Times Cited: 107
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 73
Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation
Shaowen Xie, Feiyan Zhan, Jingjie Zhu, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 13
Open Access | Times Cited: 41
The Dawn of Metal-Oxo Clusters as Artificial Proteases: From Discovery to the Present and Beyond
Francisco de Azambuja, Jens Moons, Tatjana N. Parac‐Vogt
Accounts of Chemical Research (2021) Vol. 54, Iss. 7, pp. 1673-1684
Open Access | Times Cited: 69
Indomethacin-based PROTACs as pan-coronavirus antiviral agents
Jenny Desantis, Beatrice Mercorelli, Marta Celegato, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113814-113814
Open Access | Times Cited: 67
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie Wynn, Shou‐Ching Tang
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 1, pp. 193-209
Open Access | Times Cited: 48
Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus
Zhichao Xu, Xinjin Liu, Xiaoyu Ma, et al.
Cell Insight (2022) Vol. 1, Iss. 3, pp. 100030-100030
Open Access | Times Cited: 42
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
Yue Zhong, Fanglian Chi, Hanyu Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114142-114142
Closed Access | Times Cited: 40
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)
Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, et al.
Chemical Communications (2022) Vol. 58, Iss. 29, pp. 4635-4638
Closed Access | Times Cited: 40
A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions
Le Guo, Yaxian Zhou, Xueqing Nie, et al.
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114317-114317
Open Access | Times Cited: 39
The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation
Kristin M. Riching, Elizabeth A. Caine, Marjeta Urh, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 6210-6221
Open Access | Times Cited: 38
Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation
Shaowen Xie, Jingjie Zhu, Junda Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10917-10933
Closed Access | Times Cited: 38
Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation
Haibo Xie, Chunrong Li, Hua Tang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2904-2917
Closed Access | Times Cited: 28
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhifeng Zou, Lei Yang, Hui-Jun Nie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1740-1751
Closed Access | Times Cited: 14
A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation
Qian Wang, Xingyue Yang, Ruixin Yuan, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
Debasis Das, Lingzhi Xie, Hong Jian
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 11
Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors
Katie L. Thomas, Habib Bouguenina, Daniel S. J. Miller, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 1, pp. 173-184
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top